 |
市場調查報告書
商品編碼
1789388
細胞再程式化市場（按產品、細胞來源、技術、應用、最終用戶和地區分類）Cell Reprogramming Market, By Product, By Cell Type, By Source of Cells, By Technology, By Application, By End User, By Geography |
||||||
細胞再程式化市場規模預計在 2025 年達到 4.017 億美元，預計到 2032 年將達到 7.156 億美元，2025 年至 2032 年的複合年成長率為 8.6%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年的市場規模 | 4.017億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期：2025-2032年 | 8.60% | 2032年預測 | 7.156億美元 |
全球再程式化市場代表再生醫學和生物技術領域的革命性前沿，從根本上改變了研究人員和臨床醫生處理細胞療法和疾病治療的方式。細胞重編程，即使分化細胞恢復到多功能狀態或直接轉化為其他細胞類型的過程，已成為基礎技術，實現前所未有的治療可能性。這項複雜的生物技術涵蓋多種方法，包括誘導性多功能幹細胞(iPSC) 生成、直接重編程和轉分化過程，每種方法都為個人化醫療應用提供了獨特的優勢。
該市場涵蓋一個全面的生態系統，包括研究工具、試劑、儀器和服務，協助全球學術機構、製藥公司和生物技術公司進行細胞重編程。隨著精準醫療和再生療法日益受到重視，細胞重編程技術正擴大被納入藥物研發流程、疾病建模平台以及針對先前無法治癒疾病的潛在治療性介入措施。先進的基因編輯技術、改進的再程式化通訊協定以及對細胞可塑性機制的深入理解，使該市場處於下一代醫療創新的前沿，有望重塑多個治療領域的治療模式。
市場動態
全球再程式化市場受到多個強大促進因素的支撐，這些因素正推動其強勁的擴張軌跡。慢性病、遺傳疾病和與老齡化相關的疾病日益增多，對創新治療方法的需求龐大，而細胞重編程技術正是解決這些方法獨特問題的關鍵。再生醫學研究領域的投資開放，加上政府的資助計畫和有利的法律規範，正在顯著加速市場發展。重編程方法（包括非整合方法和化學定義的通訊協定）的技術進步，正在提高效率的同時緩解安全隱患，從而擴大商業性可行性。
製藥業對個人化醫療和患者特定治療方案的日益關注，推動了基於 iPSC 的藥物篩檢和毒性測試平台的採用。然而，市場成長面臨重大限制因素，包括細胞治療方法複雜的監管途徑、實現一致重編程效率的技術挑戰、以及開發專門實驗室基礎設施的成本障礙。圍繞幹細胞研究的倫理問題和重編程通訊協定有限的標準化也對市場進入構成了障礙。關於重編程細胞基因組不穩定性及致瘤潛力的安全擔憂，帶來了監管和商業挑戰。新的機會帶來了巨大的成長潛力，特別是透過擴大在疾病建模、藥物發現加速和現成細胞療法開發的應用。生物技術公司和領先製藥公司之間的策略夥伴關係促進了技術轉移和商業化途徑。新興市場日益普及，加上人們對再生醫學益處的認知不斷提高，正在為市場參與企業創造新的收益來源和市場擴張機會。
本次調查的主要特點
- 本報告對全球細胞重編程市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。
- 它還強調了各個領域的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
- 它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數概述了全球細胞重編程市場的主要企業。
- 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
- 本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
- 相關人員將透過全球細胞重編程市場分析中使用的各種策略矩陣更輕鬆地做出決策。
目錄
第1章：調查目標和先決條件
- 調查目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
第3章：市場動態、法規與趨勢分析
- 市場動態
- 驅動程式
- 抑制因素
- 機會
- 影響分析
- 監管情景
- 產品發布/核准
- PEST分析
- 波特分析
- 併購場景
- 產業趨勢
4. 全球細胞再程式化市場（依產品分類），2020 年至 2032 年
- 介紹
- 裝置
- 耗材及套件（再程式化試劑套件、培養基及試劑、生長因子、培養器皿等）
- 軟體（細胞分析軟體、資料管理平台、流程控制軟體）
- 服務（再程式化服務、細胞株開發、品管測試）
5. 全球細胞再程式化市場（依細胞類型），2020 年至 2032 年
- 介紹
- 體細胞
- 胚胎幹細胞
- 成體幹細胞
- 癌症幹細胞
- 間質幹細胞
6. 全球細胞再程式化市場（依細胞來源分類），2020 年至 2032 年
- 介紹
- 人體細胞
- 動物細胞
7. 全球細胞再程式化市場（依技術分類），2020 年至 2032 年
- 介紹
- 利用仙台病毒進行重新編程
- mRNA再程式化
- 遊離重編程
- 基於小分子的再程式化
- 基於CRISPR或Cas9的再程式化
- 其他重編程技術
8. 全球細胞再程式化市場（按應用分類），2020 年至 2032 年
- 介紹
- 幹細胞研究
- 疾病模型
- 毒理學測試
- 藥物檢測
- 再生醫學
9. 全球細胞再程式化市場（依最終用戶分類），2020 年至 2032 年
- 介紹
- 製藥和生物技術公司
- 醫院和診所
- 合約研究組織（CRO）
- 政府和非營利組織
- 其他（學術研究機構等）
第 10 章。 2020 年至 2032 年全球細胞再程式化市場（按地區分類）價值（百萬美元）
- 介紹
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- 東南亞國協
- 其他亞太地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東地區
- 非洲
- 南非
- 北非
- 中部非洲
第11章競爭格局
- Thermo Fisher Scientific
- Merck KGaA
- Takara Bio Inc
- Lonza Group
- FUJIFILM Cellular Dynamics
- StemCell Technologies
- REPROCELL Inc
- Astellas Pharma
- Fate Therapeutics
- Cynata Therapeutics
- Pluri Inc
- ViaCyte Inc
- BlueRock Therapeutics
- Century Therapeutics
- Editas Medicine
第 12 章分析師建議
- 機會
- 一致的機會地圖
第13章參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Cell Reprogramming Market is estimated to be valued at USD 401.7 Mn in 2025 and is expected to reach USD 715.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 401.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.60% | 2032 Value Projection: | USD 715.6 Mn |
The global cell reprogramming market represents a revolutionary frontier in regenerative medicine and biotechnology, fundamentally transforming how researchers and clinicians approach cellular therapy and disease treatment. Cell reprogramming, the process of converting differentiated cells back to a pluripotent state or directly into other cell types, has emerged as a cornerstone technology enabling unprecedented therapeutic possibilities. This sophisticated biological technique encompasses various methodologies including induced pluripotent stem cell (iPSC) generation, direct reprogramming, and trans differentiation processes, each offering unique advantages for personalized medicine applications.
The market encompasses a comprehensive ecosystem of research tools, reagents, instruments, and services that facilitate cellular reprogramming across academic institutions, pharmaceutical companies, and biotechnology firms worldwide. With growing emphasis on precision medicine and regenerative therapies, cell reprogramming technologies are increasingly being integrated into drug discovery pipelines, disease modeling platforms, and potential therapeutic interventions for previously untreatable conditions. The convergence of advanced gene editing technologies, improved reprogramming protocols, and enhanced understanding of cellular plasticity mechanisms has positioned this market at the forefront of next-generation medical innovations, promising to reshape treatment paradigms across multiple therapeutic areas.
Market Dynamics
The global cell reprogramming market is propelled by several compelling drivers that collectively fuel its robust expansion trajectory. The increasing prevalence of chronic diseases, genetic disorders, and age-related conditions creates substantial demand for innovative therapeutic approaches that cell reprogramming technologies uniquely address. Growing investments in regenerative medicine research, coupled with supportive government funding initiatives and favorable regulatory frameworks, significantly accelerate market development. Technological advancements in reprogramming methodologies, including non-integrative approaches and chemically-defined protocols, enhance efficiency while reducing safety concerns, thereby expanding commercial viability.
The pharmaceutical industry's intensifying focus on personalized medicine and patient-specific therapeutic solutions drives adoption of iPSC-based drug screening and toxicity testing platforms. However, market growth faces notable restraints including complex regulatory pathways for cell-based therapies, substantial technical challenges in achieving consistent reprogramming efficiency, and significant cost barriers associated with establishing specialized laboratory infrastructure. Ethical considerations surrounding stem cell research, along with limited standardization across reprogramming protocols, create additional market entry barriers. Safety concerns regarding genomic instability and tumorigenic potential of reprogrammed cells continue to pose regulatory and commercial challenges. Nevertheless, emerging opportunities present substantial growth potential, particularly through expanding applications in disease modeling, drug discovery acceleration, and development of off-the-shelf cellular therapies. Strategic partnerships between biotechnology companies and pharmaceutical giants facilitate technology transfer and commercialization pathways. Growing adoption in emerging markets, coupled with increasing awareness of regenerative medicine benefits, creates new revenue streams and market expansion opportunities for industry participants.
Key Features of the Study
- This report provides an in-depth analysis of the global cell reprogramming market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global cell reprogramming market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Thermo Fisher Scientific, Merck KGaA, Takara Bio Inc, Lonza Group, FUJIFILM Cellular Dynamics, StemCell Technologies, REPROCELL Inc, Astellas Pharma, Fate Therapeutics, Cynata Therapeutics, Pluri Inc, ViaCyte Inc, BlueRock Therapeutics, Century Therapeutics, and Editas Medicine.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global cell reprogramming market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell reprogramming market.
Market Segmentation
- Product Insights (Revenue, USD Mn, 2020 - 2032)
- Instruments
- Reprogramming Workstations
- Bioreactors
- Microscopes
- Cell Sorters (Flow cytometers, magnetic-activated cell sorters)
- Incubators and Biostorage (CO,, incubators, cryostorage units)
- Centrifuges (Cell harvesting, processing, etc.)
- Consumables and Kits (Reprogramming Kits, Media and Reagents, Growth Factors, Culture Vessels, etc.)
- Software (Cell Analysis Software, Data Management Platforms, Process Control Software)
- Services (Reprogramming Services, Cell Line Development, Quality Control Testing)
- Cell Type Insights (Revenue, USD Mn, 2020 - 2032)
- Somatic Cells
- Embryonic Stem Cells
- Adult Stem Cells
- Cancer Stem Cells
- Mesenchymal Stem Cell
- Source of Cells Insights (Revenue, USD Mn, 2020 - 2032)
- Human Cells
- Animal Cells
- Technology Insights (Revenue, USD Mn, 2020 - 2032)
- Sendai Virus-based Reprogramming
- mRNA Reprogramming
- Episomal Reprogramming
- Small Molecule-based Reprogramming
- CRISPR or Cas9-based Reprogramming
- Other Reprogramming Technologies
- Application Insights (Revenue, USD Mn, 2020 - 2032)
- Stem Cell Research
- Disease Modeling
- Toxicology Testing
- Drug Screening
- Regenerative Medicine
- End User Insights (Revenue, USD Mn, 2020 - 2032)
- Pharmaceutical and Biotechnology Companies
- Hospitals and Clinics
- Contract Research Organizations (CROs)
- Government and Non-profit Organizations
- Others (Academic and Research Institutions, etc.)
- Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Thermo Fisher Scientific
- Merck KGaA
- Takara Bio Inc
- Lonza Group
- FUJIFILM Cellular Dynamics
- StemCell Technologies
- REPROCELL Inc
- Astellas Pharma
- Fate Therapeutics
- Cynata Therapeutics
- Pluri Inc
- ViaCyte Inc
- BlueRock Therapeutics
- Century Therapeutics
- Editas Medicine
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Cell Reprogramming Market, By Product
- Global Cell Reprogramming Market, By Cell Type
- Global Cell Reprogramming Market, By Source of Cells
- Global Cell Reprogramming Market, By Technology
- Global Cell Reprogramming Market, By Application
- Global Cell Reprogramming Market, By End User
- Global Cell Reprogramming Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Cell Reprogramming Market, By Product, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Instruments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Reprogramming Workstations
- Bioreactors
- Microscopes
- Cell Sorters (Flow cytometers, magnetic-activated cell sorters)
- Incubators and Biostorage (CO,, incubators, cryostorage units)
- Centrifuges (Cell harvesting, processing, etc.)
- Reprogramming Workstations
- Consumables and Kits (Reprogramming Kits, Media and Reagents, Growth Factors, Culture Vessels, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Software (Cell Analysis Software, Data Management Platforms, Process Control Software)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Services (Reprogramming Services, Cell Line Development, Quality Control Testing)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
5. Global Cell Reprogramming Market, By Cell Type, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Somatic Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Embryonic Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Adult Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Cancer Stem Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Mesenchymal Stem Cell
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
6. Global Cell Reprogramming Market, By Source of Cells, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Human Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Animal Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
7. Global Cell Reprogramming Market, By Technology, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Sendai Virus-based Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- mRNA Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Episomal Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Small Molecule-based Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- CRISPR or Cas9-based Reprogramming
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Other Reprogramming Technologies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
8. Global Cell Reprogramming Market, By Application, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Stem Cell Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Disease Modeling
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Toxicology Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Drug Screening
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Regenerative Medicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
9. Global Cell Reprogramming Market, By End User, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pharmaceutical and Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Goverment and Non-profit Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Others (Academic and Research Institutions, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
10. Global Cell Reprogramming Market, By Region, 2020 - 2032, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takara Bio Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lonza Group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FUJIFILM Cellular Dynamics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- StemCell Technologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- REPROCELL Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fate Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cynata Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pluri Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ViaCyte Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BlueRock Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Century Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Editas Medicine
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
